Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Two MORU colleagues and friends have made the Social Media Awards: Malaria Heroes shortlist: Sara Canavati and Cameron Conway.

Sara Canavati

An Oxford grad who has worked with SMRU and COMRU, Sara Canavati, is a senior research scientist and infectious diseases epidemiologist who has conducted clinical trials and malaria studies in the Greater Mekong subregion for the last 10 years. She is a finalist in the Regional Malaria Champion Asia Pacific category, and was nominated by the Asia Pacific Malaria Elimination Network (APMEN).

Sara’s primary research interests include malaria elimination, drug efficacy studies; artemisinin and MDR resistance; and the mobile and migrant populations at higher risk of malaria.

An active social media user since 2008 when she did her MSc at the University of Oxford, Sara strongly believes that malaria advocacy is crucial for malaria elimination.

“Scientists can benefit enormously by using social media to promote their own work and stay current in other’s scientists work,” says Sara. “Importantly, social media is a powerful tool to engage non-science audiences in malaria control and elimination. It is a very rewarding activity that all scientists should get more involved in.

Cameron Conway, a former Wellcome Trust-funded Poet in Residence at MORU, was nominated in the People’s Choice for Best Communications category. Cameron is the author of Malaria Poems, which was a 2015 Pulitzer Prize Poetry nominee.

Similar stories

How did people in Europe and SE Asia experience the first COVID-19 wave?

An international team, led by Phaik Yeong Cheah, conducted an anonymous online survey from May-June 2020, asking 5,058 people in Thailand, Malaysia, United Kingdom, Italy and Slovenia to share their experiences. Anne Osterrieder and colleagues report the unequal impacts of public health measures, and the prevalence of ‘fake news’.

Recruitment surges in COPCOV COVID-19 prevention study

As high COVID-19 daily cases and highly transmissible variants risk overwhelming countries’ healthcare systems, COPCOV, the world’s last-standing large prophylaxis RCT, faces tight timelines to determine whether chloroquine/ hydroxychloroquine prevents COVID-19

Simple blood tests may help improve malaria diagnosis in clinical studies

About one-third of children diagnosed with severe malaria may instead have an alternative cause of illness, but simple blood tests could help researchers distinguish between the two and speed up research on new treatments.

OUCRU scientists identify combination of biological markers associated with severe dengue

Nguyen Lam Vuong, Sophie Yacoub & colleagues have identified a combination of biological markers in patients with dengue that could predict whether they go on to develop moderate to severe disease. Biomarkers are used to identify the state or risk of a disease in patients; these findings could aid the development of biomarker panels for clinical use and help improve triage and risk prediction in patients with dengue.

RECOVERY trial finds Regeneron’s monoclonal antibody combination reduces deaths for hospitalised COVID-19 patients who have not mounted their own immune response

The Randomised Evaluation of COVID-19 Therapy (RECOVERY) trial has demonstrated that the investigational antibody combination developed by Regeneron reduces the risk of death when given to patients hospitalised with severe COVID-19 who have not mounted a natural antibody response of their own.

RECOVERY trial finds aspirin does not improve survival for patients hospitalised with COVID-19

The RECOVERY trial was established as a randomised clinical trial to test a range of potential treatments for patients hospitalised with COVID-19. Patients with COVID-19 are at increased risk of blood clots forming in their blood vessels, particularly in the lungs. Between November 2020 and March 2021, the RECOVERY trial included nearly 15,000 patients hospitalised with COVID-19 in an assessment of the effects of aspirin, which is widely used to reduce blood clotting in other diseases. There was no significant difference in the primary endpoint of 28-day mortality